AstraZeneca has reported strong financial results for the first half (H1) and second quarter (Q2) of 2025, highlighting continued momentum in revenue growth and excellent delivery from its research and development pipeline.

For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.

Core operating profit grew by 13 percent, while core earnings per share (EPS) increased by 17 percent to USD 4.66. The company also reported 12 positive Phase III readouts and secured 19 approvals in major markets year-to-date, further underscoring its R and D strength.

The company’s Q2 revenue alone reached USD14.5 billion, up 12 percent from the same period last year, with growth recorded across all major geographic regions.

Commenting on the results, AstraZeneca CEO Pascal Soriot said, “Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts, including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks.”

In a major strategic move, AstraZeneca has pledged a USD 50 billion investment in the United States by 2030. The cornerstone of this commitment is the construction of a new multi-billion-dollar manufacturing facility in Virginia—the single largest manufacturing investment in the company’s history.  

The facility will produce drug substances for company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. Leveraging AI, automation, and data analytics, the plant is expected to significantly enhance global production capabilities. The facility will leverage AI, automation, and data analytics to optimise production.

“This landmark investment reflects not only America’s importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca’s ambition to deliver USD 80 billion revenue by 2030,” Soriot added.

In June 2025, AstraZeneca entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group to co-develop pre-clinical therapies for chronic and immunological diseases.

In May 2025, AstraZeneca completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies. The deal, valued at up to USD 1 billion, brings EsoBiotec’s ENaBL platform into AstraZeneca’s fold, with potential applications in oncology and immune-mediated diseases.

AstraZeneca has reaffirmed its guidance for full-year 2025, expecting total revenue to grow by a high single-digit percentage and core earnings per share (EPS) to increase by a low double-digit percentage at constant exchange rates (CER).

The company anticipates a core tax rate between 18 percent and 22 percent. If foreign exchange rates from July to December 2025 remain consistent with the average rates observed in June, both total revenue and core EPS growth are expected to be broadly in line with CER growth. Previously, a low single-digit percentage adverse impact was anticipated.

Headquartered in Cambridge, UK, AstraZeneca is a global, science-led biopharmaceutical company specialising in the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, Cardiovascular, Renal and Metabolism, and Respiratory and Immunology. The company operates in over 100 countries.